Papers: 10.1155/2018/9057823

https://doi.org/10.1155/2018/9057823

Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data

Cited by: 1
Author(s): Shuo Li, Xiangyu Meng, Souraka Tapara Dramani Maman, Yong-Nong Xiao
Published: over 6 years ago

Software Mentions 1